Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvectis Pharma, Inc.NVCT · Entity 5166 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvectis Pharma, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 113,380 |
Reported balance
After 2026-06-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 35,000 · Balance 113,380 F1: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Dr. Sanchez's continued service on the Company's Board of Directors on such dates. F2: Includes 230 shares of restricted common stock that were inadvertently omitted from the initial holdings on Dr Sanchez's Form 3, filed on October 31, 2025. |
| Common StockSEC Table I · non-derivative | IndirectAs custodian for son | 415 |
Reported balance
Holding disclosure · report date 2026-06-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 415 |
Filing footnotes · ownership attribution and instrument terms
F1: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Dr. Sanchez's continued service on the Company's Board of Directors on such dates.
F2: Includes 230 shares of restricted common stock that were inadvertently omitted from the initial holdings on Dr Sanchez's Form 3, filed on October 31, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 20:11 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-073459 · tm2617536-2_4seq1.xml · nonDerivative · entry 1 Sanchez Juan · CIK 0002094238 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,380 F1 · shares: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Dr. Sanchez's continued service on the Company's Board of Directors on such dates. F2 · balance_after: Includes 230 shares of restricted common stock that were inadvertently omitted from the initial holdings on Dr Sanchez's Form 3, filed on October 31, 2025. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 13:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 13,000 | $5.79 | $75,270.00 |
DisclosureSEC source: 0001104659-25-107422 · tm2530379-2_4seq1.xml · nonDerivative · entry 1 Sanchez Juan · CIK 0002094238 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,150 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $5.77 to $5.81. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 22, 2025 Filed Oct 31, 2025 12:01 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-104664 · tm2529599-3_4seq1.xml · nonDerivative · entry 1 Sanchez Juan · CIK 0002094238 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,150 F1 · shares: The 30,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Dr. Sanchez's continued service on the Company's Board of Directors on such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.